The First Taste of the Donut Hole
This article was originally published in RPM Report
Executive Summary
The coverage gap in Medicare Part D is not taking as big a bite out of coverage this year as originally expected. But pharma is still nervous about what will happen to patients who do fall in the donut hole. And, though the numbers affected this year may not be as large as feared, pharma comapnies need to learn as much as they can about the impact of the donut hole under Part D.
You may also be interested in...
The Donut Hole Dilemma: Retaining Lost Patients Under Medicare Part D
Finally, some statistics about the impact of the Medicare Part D donut hole. The good news: drug manufacturers need not worry about most patients entering the coverage gap. The bad: a relatively large number of the industry's best customers do reduce their medication use in the donut hole-and if a customer is lost to the donut hole, they may be lost for good.
The Donut Hole Dilemma: Retaining Lost Patients Under Medicare Part D
Finally, some statistics about the impact of the Medicare Part D donut hole. The good news: drug manufacturers need not worry about most patients entering the coverage gap. The bad: a relatively large number of the industry's best customers do reduce their medication use in the donut hole-and if a customer is lost to the donut hole, they may be lost for good.
Building the Right Foundation: An Interview with Mark McClellan
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.